Document is current
Any future updates will be listed below
-
Authors
Baek, Kheewoong
Metivier, Rebecca J.
Roy Burman, Shourya S. https://orcid.org/0000-0001-9274-9104
Bushman, Jonathan W.
Yoon, Hojong
Lumpkin, Ryan J.
Ryan, Julia K.
Abeja, Dinah M.
Lakshminarayan, Megha
Yue, Hong https://orcid.org/0000-0003-4347-3193
Ojeda, Samuel
Xiong, Yuan https://orcid.org/0000-0002-2211-8267
Che, Jianwei
Verano, Alyssa L. https://orcid.org/0000-0003-2478-202X
Schmoker, Anna M. https://orcid.org/0000-0003-2830-5650
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA214608, R01CA262188, K99CA287069)
Damon Runyon Cancer Research Foundation (DRG-2514-24)
- License Information
-
More Information
Article History
Received: 6 October 2024
Accepted: 11 July 2025
First Online: 24 July 2025
Competing interests
: E.S.F. is a founder, scientific advisory board (SAB) member, and equity holder of Civetta Therapeutics, Proximity Therapeutics, Stelexis Biosciences, Neomorph, Inc. (also board of directors), and Anvia Therapeutics (also board of directors). He is an equity holder and SAB member for Avilar Therapeutics, Photys Therapeutics, and Ajax Therapeutics, and an equity holder in Lighthorse Therapeutics, and CPD4 (also board of directors). E.S.F. is a consultant to Novartis, EcoR1 Capital, Odyssey, and Deerfield. The Fischer lab receives or has received research funding from Deerfield, Novartis, Ajax, Interline, Bayer, and Astellas. K.A.D. receives or has received consulting fees from Kronos Bio and Neomorph Inc. N.S.G. is a founder, science advisory board member (SAB), and equity holder in Syros, C4, Allorion, Lighthorse, Inception, Matchpoint, Shenandoah (board member), Larkspur (board member), and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline, and Sanofi. The remaining authors declare no competing interests.
